Mirum Pharmaceuticals (NASDAQ: MIRM) has seen its shares more than double over the past year, maintaining momentum in 2026. The biotech company offers therapies for rare diseases like Alagille syndrome and bile acid disorders. While still unprofitable, Mirum’s revenue grew by 56.8% to $372.4 million in the first nine months of 2025, with a net profit in Q3. The company expects continued sales growth, targeting $630-650 million in 2026. Mirum recently acquired Bluejay Therapeutics to expand its product lineup, though short-term costs may impact profitability.

Investors considering Mirum Pharmaceuticals should note the company’s strong revenue growth and potential for profitability, despite acquisition-related costs. The stock has shown momentum, but uncertainties remain regarding future profitability. The Motley Fool Stock Advisor has identified 10 other top stocks for potential strong returns, with historical outperformance compared to the S&P 500. Consider all factors before investing in Mirum Pharmaceuticals.

Read more at Nasdaq: Is Mirum Pharmaceuticals on a Strong Path to Profitability?